ImClone

(redirected from ImClone Systems)
Also found in: Medical, Wikipedia.

ImClone

A former publicly-traded company specializing in biotechnology, particularly the development of drugs treating cancer. It is known for the insider trading scandal involving its CEO, Sam Waksal, and television personality Martha Stewart. Both served time in federal prison for attempting (Waksal) or conducting (Stewart) insider trading. Since November 2008, ImClone has been a wholly-owned subsidiary of Eli Lilly and Company. Prior to its acquisition, ImClone was traded on NASDAQ.
Mentioned in ?
References in periodicals archive ?
ImClone Systems, Bristol-Myers Squibb and Merck KGaA have had an ongoing dialogue on the clinical and regulatory development of Erbitux, including discussions regarding the size of the European colorectal trial.
A financial analysis of ImClone Systems is presented in the report which includes a ratio analysis, basic profit and loss analysis, presentation of the company balance sheet, and much more.
ImClone Systems Incorporated is committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.
ImClone Systems reported updated data from an ongoing Phase I study of IMC-1121B, which has enrolled 23 patients with advanced cancer.
Rowinsky, Chief Medical Officer and SVP of ImClone Systems.
My immediate priorities as chairman are to 1) investigate the reasons for why the relationship between ImClone Systems and its partner Bristol-Myers Squibb has seriously deteriorated over the past few years and 2) to act expeditiously to find a qualified CEO with biotechnology experience.
Fischer, Interim Chief Executive Officer of ImClone Systems.
In the short-term, ImClone Systems does not believe that the decision will materially adversely impact its operations, including the sale of ERBITUX(R) in combination with chemotherapy.
ImClone Systems Incorporated (NASDAQ: IMCL) announced today that its Board of Directors has completed a review of the Company's strategic alternatives and has made the decision to remain independent.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) and Merck KGaA, Darmstadt, Germany, announced today that they have entered into agreements amending and supplementing the 1998 development and license agreement covering ERBITUX(R) and certain other work in the field of EGFR-targeted antibodies.
ATLANTA -- ImClone Systems Incorporated (NASDAQ: IMCL) today announced findings from a Southwest Oncology Group randomized clinical trial (SWOG-0342) of ERBITUX(R) (Cetuximab), an IgG1 monoclonal antibody, in non-small cell lung cancer.
ATLANTA -- ImClone Systems Incorporated (NASDAQ: IMCL) today announced promising Phase I data on two of the Company's fully-human, IgG1 monoclonal antibodies, IMC-1121B and IMC-11F8, at the American Society of Clinical Oncology 42nd Annual Meeting in Atlanta, GA.